ArticleBMJ open sport & exercise medicine2026
Clinician-led, single-blind, randomised controlled trial evaluating the efficacy of a high-intensity resistance and impact training intervention for improving health-related quality of life in people with multiple sclerosis: protocol for STRONG-MS.
Article in BMJ open sport & exercise medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: People with multiple sclerosis (MS) engage in less physical activity and experience higher rates of osteoporosis, falls and fractures than the general population, contributing to reduced health-related quality of life (HRQoL) and increased healthcare costs. High-intensity resistance and impact training (HiRIT) has beneficial effects on bone, muscle and physical function in other populations, but its effectiveness in people with MS is unclear. Methods and analysis: STRONG-MS is a codesigned, clinician-led, single-blind, randomised controlled trial evaluating the effect of a HiRIT programme, ONERO, on HRQoL for people with MS. Secondary aims include assessing changes in bone mineral density, body composition, physical function, fatigue, mood as well as intervention safety, feasibility, acceptability, sustainability and cost-effectiveness. One hundred and eighty participants will be randomised (2:1) to ONERO or usual care for 12 months. The intervention comprises two times weekly, supervised, small-group sessions delivered by accredited allied health professionals. Outcomes will be assessed at 12 and 24 months using intention-to-treat analyses. Sustainability will be evaluated during a second 12-month period, during which participants fund ongoing participation privately or through support schemes. Ethics and dissemination: The study has approval from a Health Human Research Ethics Committee. All participants will provide written informed consent. Findings will be disseminated through peer-reviewed publications, conference presentations and summaries for participants, consumer representatives and community organisations. This study will provide novel evidence on the ability of the ONERO to improve HRQoL and musculoskeletal health in people with MS as well as its feasibility, acceptability and sustainability, to inform poststudy implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.